ADVANCED OR METASTATIC SOLID TUMORS

This early-phase trial tests a new mRNA vaccine called PAN-NeoVax, designed by artificial intelligence to target multiple cancer types. The vaccine is injected directly into tumors in 9 patients with advanced solid cancers who have run out of standard options. The main goal is to…

This early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …

This study tests a new medicine called TAK-188 in adults with advanced solid tumors that have not improved with standard treatments. TAK-188 targets and removes certain cells inside tumors that weaken the immune system, potentially allowing the body to better fight the cancer. Th…

This early-phase trial is testing a new drug called KK2260 in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test different dosing schedules in patients with esophageal or head and neck cancers. Ab…

This early-stage trial tests a new drug called KGX101, given alone or with another immunotherapy (envafolimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. About 57 p…

This study tests a new treatment using donor immune cells (CAR-NK cells) that are engineered to recognize and attack cancer. The treatment is personalized based on a tumor's unique markers. It is for adults with advanced solid tumors that have not responded to other therapies. Th…

This early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…

This early-phase trial tests CPO301, a drug designed to seek out and attack cancer cells that have a protein called EGFR on their surface. About 132 adults with advanced solid tumors (including lung, breast, and head & neck cancers) will receive the drug by IV every three weeks. …

This early-phase study tests a new drug called BH3120, alone or with pembrolizumab, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 245 p…

This early-stage trial is testing a new drug called PRTH-101, alone or with an existing immunotherapy (pembrolizumab), in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The study will enroll about 270 people and focus on safety, do…

This early-stage trial is testing a new drug called IPH4502 in people with advanced solid tumors that have a specific protein called Nectin-4. The main goals are to check the drug's safety and find the best dose. About 145 participants will receive the drug, and researchers will …

This early-stage study tests a new drug called PMC-309, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The main goal is to check safety and find the best dose. About 67 adults will take part.

This early-phase trial is testing an experimental drug called HM16390, given alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and che…

This early-phase study tests a new drug, LNCB74, in people with advanced solid tumors (ovarian, breast, endometrial, bile duct, or lung cancer) that have not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main…

This early-stage study tests a new drug called DAY301 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a powerful toxin directly to cancer cells while sparing healthy ones. The study aims to find the safest dose …